Features of the course of cardiovascular pathology and type 2 diabetes mellitus in patients with COVID-19

Vrach ◽  
2021 ◽  
Vol 32 (1) ◽  
pp. 5-8
Author(s):  
E. Polozova ◽  
V. Skvortsov ◽  
L. Chegodaeva ◽  
N. Kurkina ◽  
T. Prokhorova ◽  
...  
2020 ◽  
Vol 22 (12) ◽  
pp. 57-62
Author(s):  
Irina I. Kochergina ◽  

The article presents data on the prevalence of diabetes and prediabetes; the high compatibility of diabetes mellitus and cardiovascular pathology; high mortality among patients with diabetes mellitus and coronary heart disease, in the presence of both acute and chronic cardiovascular complications; on the important role of glucose- and lipotoxicity in the progression of carbohydrate metabolism from prediabetes to type 2 diabetes mellitus, the role of hyperglycemia in the deve-lopment of insulin resistance, atherosclerosis, hypertension, liver, kidney, endothelial dysfunction, the role of hyper- and hypoglycemia in the development of acute vascular complications – myocardial infarction, stroke, gangrene of the lower extremities; on the protective role of adiponectin – a predictor of type 2 diabetes mellitus, on the importance of glycemic control for the timely detection of early disorders of carbohydrate metabolism – impaired glucose tolerance and impaired fasting glucose; on the role of metformin in the prevention of progression of prediabetes to type 2 diabetes and cardiac pathology; on the gluco- and cardioprotective role of modern sugar-lowering drugs.


2013 ◽  
Vol 58 (6) ◽  
pp. 33-42 ◽  
Author(s):  
O. Yu. Sukhareva ◽  
I. A. Shmushkovich ◽  
E. A. Shestakova ◽  
M. V. Shestakova

Cardiovascular diseases are the commonest cause of high mortality rate among the patients with type 2 diabetes mellitus. (DM2). The safety of hypoglycemic agents considered as potential risk factors of cardiovascular pathology becomes an increasingly important concern in the choice of the strategy for the treatment of DM2 as recommended in the relevant domestic and international guidelines. The data of multifaceted action exerted by incretins on the cardiovascular system have recently become available. The potential cardioprotective properties of incretin-based pharmaceutical products and mechanisms of their action are discussed


2015 ◽  
Vol 21 ◽  
pp. 280-281
Author(s):  
Medha Munshi ◽  
Jasvinder Gill ◽  
Jason Chao ◽  
Elena Nikonova ◽  
Andreas Stuhr ◽  
...  

2015 ◽  
Vol 21 ◽  
pp. 106
Author(s):  
Franco Grimaldi ◽  
Laura Tonutti ◽  
Claudia Cipri ◽  
Cecilia Motta ◽  
Maria Antonietta Pellegrini ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document